DGAP-News: Evotec AG / Key word(s): Alliance
2016-09-22 / 07:29
The issuer is solely responsible for the content of this announcement.
---------------------------------------------------------------------------
Hamburg, Germany, 22 September 2016:
Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809)
announced today that the Company has entered into a research collaboration
with Inserm Transfert, the private subsidiary of the French National
Institute of Health and Medical Research ("Inserm").
Evotec has entered into multiple collaborations with top academic
institutions in the USA, Germany and the UK. This collaboration with Inserm
marks the initiation of the first project under Evotec's and Sanofi's
Academic Bridge, which was established as a result of the multi-component
strategic alliance between the companies effective 01 April 2015. This
Academic Bridge aims to accelerate the translation of promising
cutting-edge science from French academic institutions into pharmaceutical
product candidates. In this joint effort, Evotec scouts and incubates
projects generated in France under its EVT Innovate strategy.
A year after initiating the French Academic Bridge, the first collaboration
between Evotec and Prof. Gilles Favre's team from Inserm/the Université
Toulouse III - Paul Sabatier/Oncopole de Toulouse has started. The research
collaboration's goal is to characterise and develop new selective
modulators of RhoB functions as a promising approach to increase
therapeutic options in many cancers with high unmet medical need. RhoB is
an exciting oncological target implicated in the control of cellular stress
response, migration, tumour neovascularisation and progression.
Dr Pascale Augé, Chairman of the executive management board of Inserm
Transfert, commented: "We happily welcome the signing of this partnership
with Evotec. It will allow Prof. Favre and his team to further develop
their research in the cancer field and move to the industrial development."
Dr Cord Dohrmann, Chief Scientific Officer of Evotec, added: "We are
excited to be part of this great research initiative that combines the
best-in-class ingredients of what is needed for highly innovative and
differentiated drug candidates in oncology. This is Evotec's first of
hopefully many more academic collaborations in France. We are very proud to
add Inserm to our academic partners, thereby further broadening our efforts
to bridge leading academic science into industry standard drug discovery
programmes."
ABOUT THE FRENCH NATIONAL INSTITUTE OF HEALTH AND MEDICAL RESEARCH (INSERM)
Founded in 1964, the French National Institute of Health and Medical
Research (Inserm) is a public science and technology institute, jointly
supervised by the French Ministry of Education, higher Education and
Research and the Ministry of Social Affairs, health and women's rights. The
mission of its scientists is to study all diseases, from the most common to
the rarest, through their work in biological, medical and public health
research. Inserm supports more than 300 laboratories across France. In
total, the teams include nearly 15,000 researchers, engineers, technicians
and administrative staff, etc. Inserm is a member of the National Alliance
for Life and Health Sciences, founded in April 2009 with CNRS, Inserm, the
CEA, Inra, INRIA, the IRD, the Pasteur Institute, the Conference of
University Presidents (CPU) and the Conference of Chairmen of The Regional
and University Hospital Centres. For more information, please go to
www.inserm.fr.
ABOUT INSERM TRANSFERT
Founded in 2000, Inserm Transfert SA is the private subsidiary of the
French National Institute of Health and Medical Research (Inserm),
dedicated to technology transfer (from invention disclosure to industrial
partnership). Inserm Transfert also manages European and International
research projects, supports large scale projects in epidemiology and public
health. Inserm Transfert has run a proof of concept fund since 2009. The
company also supports entrepreneurs in the biotech sector, in partnership
with Inserm Transfert Initiative. For more information, please go to:
www.inserm-transfert.fr.
ABOUT EVOTEC AG
Evotec is a drug discovery alliance and development partnership company
focused on rapidly progressing innovative product approaches with leading
pharmaceutical and biotechnology companies, academics, patient advocacy
groups and venture capitalists. We operate worldwide providing the highest
quality stand-alone and integrated drug discovery solutions, covering all
activities from target-to-clinic to meet the industry's need for innovation
and efficiency in drug discovery (EVT Execute). The Company has established
a unique position by assembling top-class scientific experts and
integrating state-of-the-art technologies as well as substantial experience
and expertise in key therapeutic areas including neuroscience, diabetes and
complications of diabetes, pain and inflammation, oncology and infectious
diseases. On this basis, Evotec has built a broad and deep pipeline of more
than 70 partnered product opportunities at clinical, pre-clinical and
discovery stages (EVT Innovate). Evotec has established multiple long-term
discovery alliances with partners including Bayer, CHDI or UCB and
development partnerships with e.g. Janssen Pharmaceuticals in the field of
Alzheimer's disease, with MedImmune and Sanofi in the field of diabetes,
with Pfizer in the field of tissue fibrosis and with Second Genome in the
field of inflammatory diseases. For additional information please go to
www.evotec.com.
FORWARD LOOKING STATEMENTS
Information set forth in this press release contains forward-looking
statements, which involve a number of risks and uncertainties. The
forward-looking statements contained herein represent the judgement of
Evotec as of the date of this press release. Such forward-looking
statements are neither promises nor guarantees, but are subject to a
variety of risks and uncertainties, many of which are beyond our control,
and which could cause actual results to differ materially from those
contemplated in these forward-looking statements. We expressly disclaim any
obligation or undertaking to release publicly any updates or revisions to
any such statements to reflect any change in our expectations or any change
in events, conditions or circumstances on which any such statement is
based.
Contact Evotec AG:
Gabriele Hansen, VP Corporate Communications & Investor Relations, Phone:
+49.(0)40.56081-255, gabriele.hansen@evotec.com
---------------------------------------------------------------------------
2016-09-22 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Archive at www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: Evotec AG
Manfred Eigen Campus / Essener Bogen 7
22419 Hamburg
Germany
Phone: +49 (0)40 560 81-0
Fax: +49 (0)40 560 81-222
E-mail: info@evotec.com
Internet: www.evotec.com
ISIN: DE0005664809
WKN: 566480
Indices: TecDAX
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated
Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover,
Munich, Stuttgart, Tradegate Exchange
End of News DGAP News Service